Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-Insulin Therapies for Diabetes Market Size Growth Rate by Type: 2018 VS 2022 VS 2033
1.2.2 Alpha-glucosidase Inhibitors
1.2.3 Amylin Agonists
1.2.4 Biguanides
1.2.5 Dipeptidyl Peptidase-4 (DPP4) Inhibitors
1.2.6 Glinides / Meglitinides
1.2.7 GLP-1 Analogs / GLP-1 Agonists
1.2.8 Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
1.2.9 Sulfonylureas
1.2.10 Thiazolidinediones
1.2.11 Others
1.3 Market by Application
1.3.1 Global Non-Insulin Therapies for Diabetes Market Growth by Application: 2018 VS 2022 VS 2033
1.3.2 Monitoring
1.3.3 Diagnosis
1.3.4 Treatment
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Non-Insulin Therapies for Diabetes Market Perspective (2018-2033)
2.2 Non-Insulin Therapies for Diabetes Growth Trends by Region
2.2.1 Global Non-Insulin Therapies for Diabetes Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Non-Insulin Therapies for Diabetes Historic Market Size by Region (2018-2023)
2.2.3 Non-Insulin Therapies for Diabetes Forecasted Market Size by Region (2024-2033)
2.3 Non-Insulin Therapies for Diabetes Market Dynamics
2.3.1 Non-Insulin Therapies for Diabetes Industry Trends
2.3.2 Non-Insulin Therapies for Diabetes Market Drivers
2.3.3 Non-Insulin Therapies for Diabetes Market Challenges
2.3.4 Non-Insulin Therapies for Diabetes Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Non-Insulin Therapies for Diabetes Players by Revenue
3.1.1 Global Top Non-Insulin Therapies for Diabetes Players by Revenue (2018-2023)
3.1.2 Global Non-Insulin Therapies for Diabetes Revenue Market Share by Players (2018-2023)
3.2 Global Non-Insulin Therapies for Diabetes Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Non-Insulin Therapies for Diabetes Revenue
3.4 Global Non-Insulin Therapies for Diabetes Market Concentration Ratio
3.4.1 Global Non-Insulin Therapies for Diabetes Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-Insulin Therapies for Diabetes Revenue in 2022
3.5 Non-Insulin Therapies for Diabetes Key Players Head office and Area Served
3.6 Key Players Non-Insulin Therapies for Diabetes Product Solution and Service
3.7 Date of Enter into Non-Insulin Therapies for Diabetes Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-Insulin Therapies for Diabetes Breakdown Data by Type
4.1 Global Non-Insulin Therapies for Diabetes Historic Market Size by Type (2018-2023)
4.2 Global Non-Insulin Therapies for Diabetes Forecasted Market Size by Type (2024-2033)
5 Non-Insulin Therapies for Diabetes Breakdown Data by Application
5.1 Global Non-Insulin Therapies for Diabetes Historic Market Size by Application (2018-2023)
5.2 Global Non-Insulin Therapies for Diabetes Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Non-Insulin Therapies for Diabetes Market Size (2018-2033)
6.2 North America Non-Insulin Therapies for Diabetes Market Growth Rate by Country: 2018 VS 2022 VS 2033
6.3 North America Non-Insulin Therapies for Diabetes Market Size by Country (2018-2023)
6.4 North America Non-Insulin Therapies for Diabetes Market Size by Country (2024-2033)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Non-Insulin Therapies for Diabetes Market Size (2018-2033)
7.2 Europe Non-Insulin Therapies for Diabetes Market Growth Rate by Country: 2018 VS 2022 VS 2033
7.3 Europe Non-Insulin Therapies for Diabetes Market Size by Country (2018-2023)
7.4 Europe Non-Insulin Therapies for Diabetes Market Size by Country (2024-2033)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size (2018-2033)
8.2 Asia-Pacific Non-Insulin Therapies for Diabetes Market Growth Rate by Region: 2018 VS 2022 VS 2033
8.3 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Region (2018-2023)
8.4 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Region (2024-2033)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Non-Insulin Therapies for Diabetes Market Size (2018-2033)
9.2 Latin America Non-Insulin Therapies for Diabetes Market Growth Rate by Country: 2018 VS 2022 VS 2033
9.3 Latin America Non-Insulin Therapies for Diabetes Market Size by Country (2018-2023)
9.4 Latin America Non-Insulin Therapies for Diabetes Market Size by Country (2024-2033)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size (2018-2033)
10.2 Middle East & Africa Non-Insulin Therapies for Diabetes Market Growth Rate by Country: 2018 VS 2022 VS 2033
10.3 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Country (2018-2023)
10.4 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Country (2024-2033)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GSK
11.1.1 GSK Company Detail
11.1.2 GSK Business Overview
11.1.3 GSK Non-Insulin Therapies for Diabetes Introduction
11.1.4 GSK Revenue in Non-Insulin Therapies for Diabetes Business (2018-2023)
11.1.5 GSK Recent Development
11.2 Eli Lilly
11.2.1 Eli Lilly Company Detail
11.2.2 Eli Lilly Business Overview
11.2.3 Eli Lilly Non-Insulin Therapies for Diabetes Introduction
11.2.4 Eli Lilly Revenue in Non-Insulin Therapies for Diabetes Business (2018-2023)
11.2.5 Eli Lilly Recent Development
11.3 Sumitomo Dainippon Pharma
11.3.1 Sumitomo Dainippon Pharma Company Detail
11.3.2 Sumitomo Dainippon Pharma Business Overview
11.3.3 Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Introduction
11.3.4 Sumitomo Dainippon Pharma Revenue in Non-Insulin Therapies for Diabetes Business (2018-2023)
11.3.5 Sumitomo Dainippon Pharma Recent Development
11.4 Intarcia Therapeutics
11.4.1 Intarcia Therapeutics Company Detail
11.4.2 Intarcia Therapeutics Business Overview
11.4.3 Intarcia Therapeutics Non-Insulin Therapies for Diabetes Introduction
11.4.4 Intarcia Therapeutics Revenue in Non-Insulin Therapies for Diabetes Business (2018-2023)
11.4.5 Intarcia Therapeutics Recent Development
11.5 Servier
11.5.1 Servier Company Detail
11.5.2 Servier Business Overview
11.5.3 Servier Non-Insulin Therapies for Diabetes Introduction
11.5.4 Servier Revenue in Non-Insulin Therapies for Diabetes Business (2018-2023)
11.5.5 Servier Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Detail
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Non-Insulin Therapies for Diabetes Introduction
11.6.4 Pfizer Revenue in Non-Insulin Therapies for Diabetes Business (2018-2023)
11.6.5 Pfizer Recent Development
11.7 Merck
11.7.1 Merck Company Detail
11.7.2 Merck Business Overview
11.7.3 Merck Non-Insulin Therapies for Diabetes Introduction
11.7.4 Merck Revenue in Non-Insulin Therapies for Diabetes Business (2018-2023)
11.7.5 Merck Recent Development
11.8 Dong-A Pharmaceutical
11.8.1 Dong-A Pharmaceutical Company Detail
11.8.2 Dong-A Pharmaceutical Business Overview
11.8.3 Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Introduction
11.8.4 Dong-A Pharmaceutical Revenue in Non-Insulin Therapies for Diabetes Business (2018-2023)
11.8.5 Dong-A Pharmaceutical Recent Development
11.9 Luye Pharma Group
11.9.1 Luye Pharma Group Company Detail
11.9.2 Luye Pharma Group Business Overview
11.9.3 Luye Pharma Group Non-Insulin Therapies for Diabetes Introduction
11.9.4 Luye Pharma Group Revenue in Non-Insulin Therapies for Diabetes Business (2018-2023)
11.9.5 Luye Pharma Group Recent Development
11.10 Eurofarma
11.10.1 Eurofarma Company Detail
11.10.2 Eurofarma Business Overview
11.10.3 Eurofarma Non-Insulin Therapies for Diabetes Introduction
11.10.4 Eurofarma Revenue in Non-Insulin Therapies for Diabetes Business (2018-2023)
11.10.5 Eurofarma Recent Development
11.11 Geropharm
11.11.1 Geropharm Company Detail
11.11.2 Geropharm Business Overview
11.11.3 Geropharm Non-Insulin Therapies for Diabetes Introduction
11.11.4 Geropharm Revenue in Non-Insulin Therapies for Diabetes Business (2018-2023)
11.11.5 Geropharm Recent Development
11.12 Alkem Labs
11.12.1 Alkem Labs Company Detail
11.12.2 Alkem Labs Business Overview
11.12.3 Alkem Labs Non-Insulin Therapies for Diabetes Introduction
11.12.4 Alkem Labs Revenue in Non-Insulin Therapies for Diabetes Business (2018-2023)
11.12.5 Alkem Labs Recent Development
11.13 SatRx
11.13.1 SatRx Company Detail
11.13.2 SatRx Business Overview
11.13.3 SatRx Non-Insulin Therapies for Diabetes Introduction
11.13.4 SatRx Revenue in Non-Insulin Therapies for Diabetes Business (2018-2023)
11.13.5 SatRx Recent Development
11.14 Jiangsu Hansoh Pharmaceutical
11.14.1 Jiangsu Hansoh Pharmaceutical Company Detail
11.14.2 Jiangsu Hansoh Pharmaceutical Business Overview
11.14.3 Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Introduction
11.14.4 Jiangsu Hansoh Pharmaceutical Revenue in Non-Insulin Therapies for Diabetes Business (2018-2023)
11.14.5 Jiangsu Hansoh Pharmaceutical Recent Development
11.15 Novo Nordisk
11.15.1 Novo Nordisk Company Detail
11.15.2 Novo Nordisk Business Overview
11.15.3 Novo Nordisk Non-Insulin Therapies for Diabetes Introduction
11.15.4 Novo Nordisk Revenue in Non-Insulin Therapies for Diabetes Business (2018-2023)
11.15.5 Novo Nordisk Recent Development
11.16 Emisphere
11.16.1 Emisphere Company Detail
11.16.2 Emisphere Business Overview
11.16.3 Emisphere Non-Insulin Therapies for Diabetes Introduction
11.16.4 Emisphere Revenue in Non-Insulin Therapies for Diabetes Business (2018-2023)
11.16.5 Emisphere Recent Development
11.17 Uni-Bio Science Group
11.17.1 Uni-Bio Science Group Company Detail
11.17.2 Uni-Bio Science Group Business Overview
11.17.3 Uni-Bio Science Group Non-Insulin Therapies for Diabetes Introduction
11.17.4 Uni-Bio Science Group Revenue in Non-Insulin Therapies for Diabetes Business (2018-2023)
11.17.5 Uni-Bio Science Group Recent Development
11.18 Takeda
11.18.1 Takeda Company Detail
11.18.2 Takeda Business Overview
11.18.3 Takeda Non-Insulin Therapies for Diabetes Introduction
11.18.4 Takeda Revenue in Non-Insulin Therapies for Diabetes Business (2018-2023)
11.18.5 Takeda Recent Development
11.19 3SBio
11.19.1 3SBio Company Detail
11.19.2 3SBio Business Overview
11.19.3 3SBio Non-Insulin Therapies for Diabetes Introduction
11.19.4 3SBio Revenue in Non-Insulin Therapies for Diabetes Business (2018-2023)
11.19.5 3SBio Recent Development
11.20 Jiangsu Hengrui Medicine
11.20.1 Jiangsu Hengrui Medicine Company Detail
11.20.2 Jiangsu Hengrui Medicine Business Overview
11.20.3 Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Introduction
11.20.4 Jiangsu Hengrui Medicine Revenue in Non-Insulin Therapies for Diabetes Business (2018-2023)
11.20.5 Jiangsu Hengrui Medicine Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Non-Insulin Therapies for Diabetes Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2033
Table 2. Key Players of Alpha-glucosidase Inhibitors
Table 3. Key Players of Amylin Agonists
Table 4. Key Players of Biguanides
Table 5. Key Players of Dipeptidyl Peptidase-4 (DPP4) Inhibitors
Table 6. Key Players of Glinides / Meglitinides
Table 7. Key Players of GLP-1 Analogs / GLP-1 Agonists
Table 8. Key Players of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
Table 9. Key Players of Sulfonylureas
Table 10. Key Players of Thiazolidinediones
Table 11. Key Players of Others
Table 12. Global Non-Insulin Therapies for Diabetes Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2033
Table 13. Global Non-Insulin Therapies for Diabetes Market Size by Region (US$ Million): 2018 VS 2022 VS 2033
Table 14. Global Non-Insulin Therapies for Diabetes Market Size by Region (2018-2023) & (US$ Million)
Table 15. Global Non-Insulin Therapies for Diabetes Market Share by Region (2018-2023)
Table 16. Global Non-Insulin Therapies for Diabetes Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 17. Global Non-Insulin Therapies for Diabetes Market Share by Region (2024-2033)
Table 18. Non-Insulin Therapies for Diabetes Market Trends
Table 19. Non-Insulin Therapies for Diabetes Market Drivers
Table 20. Non-Insulin Therapies for Diabetes Market Challenges
Table 21. Non-Insulin Therapies for Diabetes Market Restraints
Table 22. Global Non-Insulin Therapies for Diabetes Revenue by Players (2018-2023) & (US$ Million)
Table 23. Global Non-Insulin Therapies for Diabetes Market Share by Players (2018-2023)
Table 24. Global Top Non-Insulin Therapies for Diabetes Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Insulin Therapies for Diabetes as of 2022)
Table 25. Ranking of Global Top Non-Insulin Therapies for Diabetes Companies by Revenue (US$ Million) in 2022
Table 26. Global 5 Largest Players Market Share by Non-Insulin Therapies for Diabetes Revenue (CR5 and HHI) & (2018-2023)
Table 27. Key Players Headquarters and Area Served
Table 28. Key Players Non-Insulin Therapies for Diabetes Product Solution and Service
Table 29. Date of Enter into Non-Insulin Therapies for Diabetes Market
Table 30. Mergers & Acquisitions, Expansion Plans
Table 31. Global Non-Insulin Therapies for Diabetes Market Size by Type (2018-2023) & (US$ Million)
Table 32. Global Non-Insulin Therapies for Diabetes Revenue Market Share by Type (2018-2023)
Table 33. Global Non-Insulin Therapies for Diabetes Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 34. Global Non-Insulin Therapies for Diabetes Revenue Market Share by Type (2024-2033)
Table 35. Global Non-Insulin Therapies for Diabetes Market Size by Application (2018-2023) & (US$ Million)
Table 36. Global Non-Insulin Therapies for Diabetes Revenue Market Share by Application (2018-2023)
Table 37. Global Non-Insulin Therapies for Diabetes Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 38. Global Non-Insulin Therapies for Diabetes Revenue Market Share by Application (2024-2033)
Table 39. North America Non-Insulin Therapies for Diabetes Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 40. North America Non-Insulin Therapies for Diabetes Market Size by Country (2018-2023) & (US$ Million)
Table 41. North America Non-Insulin Therapies for Diabetes Market Size by Country (2024-2033) & (US$ Million)
Table 42. Europe Non-Insulin Therapies for Diabetes Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 43. Europe Non-Insulin Therapies for Diabetes Market Size by Country (2018-2023) & (US$ Million)
Table 44. Europe Non-Insulin Therapies for Diabetes Market Size by Country (2024-2033) & (US$ Million)
Table 45. Asia-Pacific Non-Insulin Therapies for Diabetes Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2033
Table 46. Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Region (2018-2023) & (US$ Million)
Table 47. Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Region (2024-2033) & (US$ Million)
Table 48. Latin America Non-Insulin Therapies for Diabetes Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 49. Latin America Non-Insulin Therapies for Diabetes Market Size by Country (2018-2023) & (US$ Million)
Table 50. Latin America Non-Insulin Therapies for Diabetes Market Size by Country (2024-2033) & (US$ Million)
Table 51. Middle East & Africa Non-Insulin Therapies for Diabetes Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 52. Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Country (2018-2023) & (US$ Million)
Table 53. Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Country (2024-2033) & (US$ Million)
Table 54. GSK Company Detail
Table 55. GSK Business Overview
Table 56. GSK Non-Insulin Therapies for Diabetes Product
Table 57. GSK Revenue in Non-Insulin Therapies for Diabetes Business (2018-2023) & (US$ Million)
Table 58. GSK Recent Development
Table 59. Eli Lilly Company Detail
Table 60. Eli Lilly Business Overview
Table 61. Eli Lilly Non-Insulin Therapies for Diabetes Product
Table 62. Eli Lilly Revenue in Non-Insulin Therapies for Diabetes Business (2018-2023) & (US$ Million)
Table 63. Eli Lilly Recent Development
Table 64. Sumitomo Dainippon Pharma Company Detail
Table 65. Sumitomo Dainippon Pharma Business Overview
Table 66. Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Product
Table 67. Sumitomo Dainippon Pharma Revenue in Non-Insulin Therapies for Diabetes Business (2018-2023) & (US$ Million)
Table 68. Sumitomo Dainippon Pharma Recent Development
Table 69. Intarcia Therapeutics Company Detail
Table 70. Intarcia Therapeutics Business Overview
Table 71. Intarcia Therapeutics Non-Insulin Therapies for Diabetes Product
Table 72. Intarcia Therapeutics Revenue in Non-Insulin Therapies for Diabetes Business (2018-2023) & (US$ Million)
Table 73. Intarcia Therapeutics Recent Development
Table 74. Servier Company Detail
Table 75. Servier Business Overview
Table 76. Servier Non-Insulin Therapies for Diabetes Product
Table 77. Servier Revenue in Non-Insulin Therapies for Diabetes Business (2018-2023) & (US$ Million)
Table 78. Servier Recent Development
Table 79. Pfizer Company Detail
Table 80. Pfizer Business Overview
Table 81. Pfizer Non-Insulin Therapies for Diabetes Product
Table 82. Pfizer Revenue in Non-Insulin Therapies for Diabetes Business (2018-2023) & (US$ Million)
Table 83. Pfizer Recent Development
Table 84. Merck Company Detail
Table 85. Merck Business Overview
Table 86. Merck Non-Insulin Therapies for Diabetes Product
Table 87. Merck Revenue in Non-Insulin Therapies for Diabetes Business (2018-2023) & (US$ Million)
Table 88. Merck Recent Development
Table 89. Dong-A Pharmaceutical Company Detail
Table 90. Dong-A Pharmaceutical Business Overview
Table 91. Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Product
Table 92. Dong-A Pharmaceutical Revenue in Non-Insulin Therapies for Diabetes Business (2018-2023) & (US$ Million)
Table 93. Dong-A Pharmaceutical Recent Development
Table 94. Luye Pharma Group Company Detail
Table 95. Luye Pharma Group Business Overview
Table 96. Luye Pharma Group Non-Insulin Therapies for Diabetes Product
Table 97. Luye Pharma Group Revenue in Non-Insulin Therapies for Diabetes Business (2018-2023) & (US$ Million)
Table 98. Luye Pharma Group Recent Development
Table 99. Eurofarma Company Detail
Table 100. Eurofarma Business Overview
Table 101. Eurofarma Non-Insulin Therapies for Diabetes Product
Table 102. Eurofarma Revenue in Non-Insulin Therapies for Diabetes Business (2018-2023) & (US$ Million)
Table 103. Eurofarma Recent Development
Table 104. Geropharm Company Detail
Table 105. Geropharm Business Overview
Table 106. Geropharm Non-Insulin Therapies for Diabetes Product
Table 107. Geropharm Revenue in Non-Insulin Therapies for Diabetes Business (2018-2023) & (US$ Million)
Table 108. Geropharm Recent Development
Table 109. Alkem Labs Company Detail
Table 110. Alkem Labs Business Overview
Table 111. Alkem Labs Non-Insulin Therapies for Diabetes Product
Table 112. Alkem Labs Revenue in Non-Insulin Therapies for Diabetes Business (2018-2023) & (US$ Million)
Table 113. Alkem Labs Recent Development
Table 114. SatRx Company Detail
Table 115. SatRx Business Overview
Table 116. SatRx Non-Insulin Therapies for Diabetes Product
Table 117. SatRx Revenue in Non-Insulin Therapies for Diabetes Business (2018-2023) & (US$ Million)
Table 118. SatRx Recent Development
Table 119. Jiangsu Hansoh Pharmaceutical Company Detail
Table 120. Jiangsu Hansoh Pharmaceutical Business Overview
Table 121. Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Product
Table 122. Jiangsu Hansoh Pharmaceutical Revenue in Non-Insulin Therapies for Diabetes Business (2018-2023) & (US$ Million)
Table 123. Jiangsu Hansoh Pharmaceutical Recent Development
Table 124. Novo Nordisk Company Detail
Table 125. Novo Nordisk Business Overview
Table 126. Novo Nordisk Non-Insulin Therapies for Diabetes Product
Table 127. Novo Nordisk Revenue in Non-Insulin Therapies for Diabetes Business (2018-2023) & (US$ Million)
Table 128. Novo Nordisk Recent Development
Table 129. Emisphere Company Detail
Table 130. Emisphere Business Overview
Table 131. Emisphere Non-Insulin Therapies for Diabetes Product
Table 132. Emisphere Revenue in Non-Insulin Therapies for Diabetes Business (2018-2023) & (US$ Million)
Table 133. Emisphere Recent Development
Table 134. Uni-Bio Science Group Company Detail
Table 135. Uni-Bio Science Group Business Overview
Table 136. Uni-Bio Science Group Non-Insulin Therapies for Diabetes Product
Table 137. Uni-Bio Science Group Revenue in Non-Insulin Therapies for Diabetes Business (2018-2023) & (US$ Million)
Table 138. Uni-Bio Science Group Recent Development
Table 139. Takeda Company Detail
Table 140. Takeda Business Overview
Table 141. Takeda Non-Insulin Therapies for Diabetes Product
Table 142. Takeda Revenue in Non-Insulin Therapies for Diabetes Business (2018-2023) & (US$ Million)
Table 143. Takeda Recent Development
Table 144. 3SBio Company Detail
Table 145. 3SBio Business Overview
Table 146. 3SBio Non-Insulin Therapies for Diabetes Product
Table 147. 3SBio Revenue in Non-Insulin Therapies for Diabetes Business (2018-2023) & (US$ Million)
Table 148. 3SBio Recent Development
Table 149. Jiangsu Hengrui Medicine Company Detail
Table 150. Jiangsu Hengrui Medicine Business Overview
Table 151. Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Product
Table 152. Jiangsu Hengrui Medicine Revenue in Non-Insulin Therapies for Diabetes Business (2018-2023) & (US$ Million)
Table 153. Jiangsu Hengrui Medicine Recent Development
Table 154. Research Programs/Design for This Report
Table 155. Key Data Information from Secondary Sources
Table 156. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Non-Insulin Therapies for Diabetes Market Size Comparison by Type (2023-2033) & (US$ Million)
Figure 2. Global Non-Insulin Therapies for Diabetes Market Share by Type: 2022 VS 2033
Figure 3. Alpha-glucosidase Inhibitors Features
Figure 4. Amylin Agonists Features
Figure 5. Biguanides Features
Figure 6. Dipeptidyl Peptidase-4 (DPP4) Inhibitors Features
Figure 7. Glinides / Meglitinides Features
Figure 8. GLP-1 Analogs / GLP-1 Agonists Features
Figure 9. Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Features
Figure 10. Sulfonylureas Features
Figure 11. Thiazolidinediones Features
Figure 12. Others Features
Figure 13. Global Non-Insulin Therapies for Diabetes Market Size Comparison by Application (2023-2033) & (US$ Million)
Figure 14. Global Non-Insulin Therapies for Diabetes Market Share by Application: 2022 VS 2033
Figure 15. Monitoring Case Studies
Figure 16. Diagnosis Case Studies
Figure 17. Treatment Case Studies
Figure 18. Others Case Studies
Figure 19. Non-Insulin Therapies for Diabetes Report Years Considered
Figure 20. Global Non-Insulin Therapies for Diabetes Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 21. Global Non-Insulin Therapies for Diabetes Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 22. Global Non-Insulin Therapies for Diabetes Market Share by Region: 2022 VS 2033
Figure 23. Global Non-Insulin Therapies for Diabetes Market Share by Players in 2022
Figure 24. Global Top Non-Insulin Therapies for Diabetes Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Insulin Therapies for Diabetes as of 2022)
Figure 25. The Top 10 and 5 Players Market Share by Non-Insulin Therapies for Diabetes Revenue in 2022
Figure 26. North America Non-Insulin Therapies for Diabetes Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 27. North America Non-Insulin Therapies for Diabetes Market Share by Country (2018-2033)
Figure 28. United States Non-Insulin Therapies for Diabetes Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. Canada Non-Insulin Therapies for Diabetes Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. Europe Non-Insulin Therapies for Diabetes Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 31. Europe Non-Insulin Therapies for Diabetes Market Share by Country (2018-2033)
Figure 32. Germany Non-Insulin Therapies for Diabetes Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. France Non-Insulin Therapies for Diabetes Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 34. U.K. Non-Insulin Therapies for Diabetes Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. Italy Non-Insulin Therapies for Diabetes Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. Russia Non-Insulin Therapies for Diabetes Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 37. Nordic Countries Non-Insulin Therapies for Diabetes Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 38. Asia-Pacific Non-Insulin Therapies for Diabetes Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 39. Asia-Pacific Non-Insulin Therapies for Diabetes Market Share by Region (2018-2033)
Figure 40. China Non-Insulin Therapies for Diabetes Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 41. Japan Non-Insulin Therapies for Diabetes Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 42. South Korea Non-Insulin Therapies for Diabetes Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 43. Southeast Asia Non-Insulin Therapies for Diabetes Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. India Non-Insulin Therapies for Diabetes Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. Australia Non-Insulin Therapies for Diabetes Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 46. Latin America Non-Insulin Therapies for Diabetes Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 47. Latin America Non-Insulin Therapies for Diabetes Market Share by Country (2018-2033)
Figure 48. Mexico Non-Insulin Therapies for Diabetes Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 49. Brazil Non-Insulin Therapies for Diabetes Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 50. Middle East & Africa Non-Insulin Therapies for Diabetes Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 51. Middle East & Africa Non-Insulin Therapies for Diabetes Market Share by Country (2018-2033)
Figure 52. Turkey Non-Insulin Therapies for Diabetes Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 53. Saudi Arabia Non-Insulin Therapies for Diabetes Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 54. GSK Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2018-2023)
Figure 55. Eli Lilly Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2018-2023)
Figure 56. Sumitomo Dainippon Pharma Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2018-2023)
Figure 57. Intarcia Therapeutics Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2018-2023)
Figure 58. Servier Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2018-2023)
Figure 59. Pfizer Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2018-2023)
Figure 60. Merck Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2018-2023)
Figure 61. Dong-A Pharmaceutical Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2018-2023)
Figure 62. Luye Pharma Group Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2018-2023)
Figure 63. Eurofarma Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2018-2023)
Figure 64. Geropharm Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2018-2023)
Figure 65. Alkem Labs Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2018-2023)
Figure 66. SatRx Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2018-2023)
Figure 67. Jiangsu Hansoh Pharmaceutical Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2018-2023)
Figure 68. Novo Nordisk Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2018-2023)
Figure 69. Emisphere Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2018-2023)
Figure 70. Uni-Bio Science Group Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2018-2023)
Figure 71. Takeda Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2018-2023)
Figure 72. 3SBio Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2018-2023)
Figure 73. Jiangsu Hengrui Medicine Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2018-2023)
Figure 74. Bottom-up and Top-down Approaches for This Report
Figure 75. Data Triangulation
Figure 76. Key Executives Interviewed